Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)

• Status: Completed
• Trial end date: 2002-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate the relative bioavailability of Naproxen delayed-release tablets (375 mg).

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sandoz
• Treatments: Naproxen

Criteria

Inclusion Criteria:

• No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

• Positive test results for HIV or hepatitis B or C.

• Treatment for drug or alcohol dependence.